|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment显示文摘Spondyloarthropathies(SpA) include many different forms of inflammatory arthritis and can affect the spine(axial SpA) and/or peripheral joints(peripheral SpA) with Ankylosing spondylitis(AS) being the prototype of the former. Extraarticular manifestations, like uveitis, psoriasis and inflammatory bowel disease(IBD) are frequently observed in the setting of SpA and are, in fact, part of the SpA classification criteria. Bowel involvement seems to be the most common of these manifestations. Clinically evident IBD is observed in 6%-14% of AS patients, which is significantly more frequent compared to the general population. Besides, it seems that silent microscopic gut inflammation, is evident in around 60% in AS patients. Interestingly, occurrence of IBD has been associated with AS disease activity. For peripheral SpA, two different forms have been proposed with diverse characteristics. Of note, SpA(axial or peripheral) is more commonly observed in Crohn's disease than in ulcerative colitis. The common pathogenetic mechanisms that explain the link between IBD and SpA are still ill-defined. The role of dysregulated microbiome along with migration of T lymphocytes and other cells from gut to the joint('gut-joint' axis) has been recognized, in the context of a genetic background including associations with alleles inside or outside the human leukocyte antigen system. Various therapeutic modalities are available with monoclonal antibodies against tumour necrosis factor, interleukin-23 and interleukin-17, being the most effective. Both gastroenterologists and rheumatologists should be alert to identify the coexistence of these conditions and ideally follow-up these patients in combined clinics. | George E Fragoulis Christina Liava Dimitrios Daoussis Euangelos Akriviadis Alexandros Garyfallos Theodoros Dimitroulas | 2019 | World Journal of Gastroenterology2019，25，18： | 13 |
| 2 | Evidence that DKK-l is dysfunctional in ankylosing spondylitis显示文摘 | Daoussis D Liossis SN Solomou EE et a1 | 2010 | Arthritis Rheum2010，62，1： | 1 |
| 3 | The emerging role of Dickkopf-1 in bone biology:is it the main switch controlling bone and joint remodling显示文摘 | Daoussis D Andonopoulos AP | 2011 | Semin Arthritis Rheum2011，41，2： | 1 |
| 4 | Targeting CD40L:a promising therapeutic approach显示文摘 | Daoussis D Andonopoulos A P Liossis S N | 2004 | Clin Diagn Lab Immunol2004，11，4： | 1 |
| 5 | Evidence that Dkk 1 is dysfunctional in ankylosing spondylitis 显示文摘 | Daoussis D Liossis SNC Solomou EE | 2010 | Arthritis Rheum2010，62，1： | 1 |
| 6 | Cardiovascular risk factors and not disease activity,severity or therapy associate with renal dysfunction in patients with rheumatoid arthritis显示文摘 | Daoussis D Panoulas VF Antonopoulos I | 2010 | Ann Rheum Dis2010，69，3： | 1 |
| 7 | Experience with rituximab in scleroderma:results from a 1-year,proof-ofprinciple study显示文摘 | Daoussis D Liossis SN Tsamandas AC | 2010 | Rheumatology (Oxford)2010，49，2： | 1 |
| 8 | Sublimation Kinetics and Sublimation End-Point Times during Freeze-Drying of Pharmaceutical Active Principle with Organic Co-Solvent formulations显示文摘 | Rim Daoussi Séverine Vessot Julien Andrieu | | 0，，87： | 1 |
| 9 | Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis显示文摘 | Daoussis D Liossis SN Solomou EE | 2010 | Arthritis Rheum2010，62，1： | 1 |
| 10 | Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis显示文摘 | Daoussis D Liossis S N Solomou E E | | 0，，01： | 1 |
| 11 | The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remod- eling?显示文摘 | Daoussis D Andonopoulos AP | 2011 | Semin Arthritis Rheum2011，41，2： | 1 |
| 12 | Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis显示文摘 | Daoussis D Liossis SN Tsamandas AC | 2012 | Clin Exp Rheumatol2012，30，271： | 1 |
| 13 | B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin显示文摘 | Daoussis D Tsamandas AC Liossis SN | 2012 | Arthritis Res Ther2012，14，3： | 1 |
| 14 | Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis 显示文摘 | Daoussis D Liossis SN Solomou EE | 2010 | Arthritis Rheum2010，62，1： | 1 |
| 15 | Treatment of systemic sclerosis-associated calcinosis: a ease report of rituximab-indueed regression of CREST-related ealcinosis and review of the literature 显示文摘 | Daoussis D Antonopoulos I Liossis SN | 2012 | Semiu Arthritis Rheum2012，41，6： | 1 |
| 16 | épilepsie temporale symptomatique d’une méningocèle intracranienne chez une patiente atteinte de neurofibromatose de type 1显示文摘 | A. Boughammoura N. Daoussi S. Younes M. Kilani S. Chebel M. Hattab M. Frih-Ayed | 2013 | Neurochirurgie (-)2013，，4： | 1 |
| 17 | Experience with ritux-imab in scleroderma : results from a 1 -year, proof-of-principle study显示文摘 | Daoussis D Liossis SN Tsamandas AC | 2010 | Rheumatology( Oxford)2010，49，： | 1 |
| 18 | Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis显示文摘 | Daoussis D Liossis SN Solomou EE | | 0，，01： | 1 |
| 19 | Evidence that Dkk-I is dysfunctional in ankylosing spondylitis 显示文摘 | Daoussis D Liossis SN Solomou EE | 2010 | Arthritis Rheum2010，62，： | 1 |
| 20 | Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis显示文摘 | DAOUSSIS D LIOSSIS S N SOLOMOU E E | 2010 | Arthritis Rheum2010，62，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员